NCT03915678: Atezolizumab Combined With Intratumoral G100 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

NCT03915678
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with evidence of progressive or symptomatic central nervous system (CNS) or leptomeningeal metastases; Patients with prior treatment with atezolizumab or therapy with an anti-PD-1, anti-PD-L1, & anti-PD-L2
https://ClinicalTrials.gov/show/NCT03915678

Comments are closed.

Up ↑